TYK MEDICINES-B (02410) rose more than 10%, and as of the time of writing, it was up 7.97% to HKD 13.95, with a turnover of HKD 32.6634 million. On January 6, the CDE website indicated that the Mesylate Edotinib Tablets (TY-9591 tablets) declared by TYK MEDICINES are planned to be included in the priority review process. The drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, and are accompanied by central nervous system (CNS) metastases. It is worth mentioning that at the World Lung Cancer Congress last September, the key Phase II clinical trial results for Edotinib tablets targeting NSCLC brain metastases, released by TYK MEDICINES, garnered significant attention from industry peers.